Sotorasib: First Approval - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34357500/
Sotorasib (LUMAKRAS ™ ) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and...
Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34359807/
Non-small cell lung cancer has a 5-year survival rate of less than 12-15%, calling for the development of additional therapeutic strategies to combat this disease. Here we tested the efficacy...
Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34344387/
Our results confirm the conclusion of recent reports that the Idylla™EGFR assay is not suitable in a resistance to EGFR TKI setting, also not in our cytological NSCLC samples prepared...
Nice to see this option on the Neogenomics online requisition.
Analysts expect blockbuster revenues in the coming years
How's Amgen's key KRAS launch looking? It's too early for meaningful sales, but expectations are riding high
It's only been about two months since Amgen's hot new KRAS inhibitor Lumakras won FDA approval, but it's clear the drug is already shouldering big expectations. While the company didn't...